Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate

Drug Metabolism and Disposition

Volumn 40, Issue 5, 2012, Pages 970-981

  Coughlin, John E ^a   Pandey, Rajendra K ^a   Padmanabhan, Seetharamaiyer ^a   O'Loughlin, Kathleen G ^b   Marquis, Judith ^c   Green, Carol E ^b   Mirsalis, Jon C ^b   Iyer, Radhakrishnan P ^a  

^a Spring Bank Pharmaceuticals Inc S 7   (United States)

^b SRI INTERNATIONAL   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DINUCLEOSIDE PHOSPHORODITHIOATE; DINUCLEOSIDE PHOSPHORODITHIOATE S 35; ESTERASE; PRODRUG; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIFFUSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHOBICITY; INTESTINE FLUID; ISOTOPE LABELING; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; RAT; SOLID PHASE SYNTHESIS; STOMACH JUICE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DESIGN; DRUG STABILITY; FEMALE; GASTRIC JUICE; HEPATITIS B VIRUS; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL SECRETIONS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TISSUE DISTRIBUTION;

HEPATITIS B VIRUS; RATTUS;

EID: 84859901133     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044446     Document Type: Article

References (49)

1. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, and Jiang Z (1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50:571-576.
2. Ahmad A and Mond JJ (1985) 8-Hydroxyguanosine and 8-methoxyguanosine possess immunostimulating activity for B lymphocytes. Cell Immunol 94:276-280. (Pubitemid 15247812)
3. Akira S, Uematsu S, and Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783-801. (Pubitemid 43261452)
4. Beaucage SL and Iyer RP (1992) Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:2223-2311.
5. Coughlin JE, Padmanabhan S, Zhang G, Kirk CJ, Govardhan CP, Korba BE, O'Loughlin K, Green CE, Mirsalis J, Morrey JD, et al. (2010) Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. Bioorg Med Chem Lett 20:1783-1786.
6. Crooke RM, Graham MJ, Martin MJ, Lemonidis KM, Wyrzykiewiecz T, and Cummins LL (2000) Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther 292:140-149. (Pubitemid 30026364)
7. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
8. Dias N and Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1:347-355.
9. Ellington AD and Conrad R (1995) Aptamers as potential nucleic acid pharmaceuticals. Biotechnol Annu Rev 1:185-214.
10. Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5:381-391.
11. Gibaldi M, Boyes RN, and Feldman S (1971) Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci 60:1338-1340.
12. Hannon GJ (2002) RNA interference. Nature 418:244-251.
13. Hannoush RN, Min KL, and Damha MJ (2004) Diversity-oriented solid-phase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors. Nucleic Acids Res 32:6164-6175.
14. Henry SP, Monteith D, and Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:395-408. (Pubitemid 27292375)
15. Henry SP, Templin MV, Gillett N, Rojko J, and Levin AA (1999) Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 27:95-100. (Pubitemid 29075751)
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Iyer RP, Regan JB, Egan W, and Beaucage SL (1990a) 3H-1,2-benzodithiol-3- one 1, 1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphoramidites. J Am Chem Soc 112:1253-1254. (Pubitemid 20127085)
18. Iyer RP, Phillips LR, Egan W, Regan JB, and Beaucage SL (1990b) The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one-1, 1-dioxide as a sulfur-transfer reagent. J Org Chem 55:4693-4699. (Pubitemid 20274274)
19. Iyer RP, Tan W, Yu D, and Agrawal S (1994) Synthesis of [35S]-3H-1, 2-benzodithiol-3-one-1,1-dioxide: application in the preparation of site-specifically 35S-labeled oligonucleotides. Tetrahedron Lett 35:9521-9524.
20. Iyer RP, Jin Y, Roland A, Morrey JD, Mounir S, and Korba B (2004a) Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents. Antimicrob Agents Chemother 48:2199-2205. (Pubitemid 38691619)
21. Iyer RP, Roland A, Jin Y, Mounir S, Korba B, Julander JG, and Morrey JD (2004b) Antihepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother 48:2318-2320. (Pubitemid 38691641)
22. Iyer RP, Coughlin JE, and Padmanabhan S (2005a) Rapid functionalization and loading of solid supports. Org Prep Proc Int 37:205-212. (Pubitemid 40874826)
23. Iyer RP, Padmanabhan S, Zhang G, Morrey JD, and Korba BE (2005b) Nucleotide analogs as novel anti-hepatitis B virus agents. Curr Opin Pharmacol 5:520-528. (Pubitemid 41258571)
24. Iyer RP, Coughlin J, and Padmanabhan S (2006) Metabolism and pharmacokinetic studies of SB 9000-a novel anti-HBV agent. Abstracts of the 19th International Conference on Antiviral Research; 2006 Apr 29-May 3; Palm Springs, CA. International Society for Antiviral Research, Washington, DC.
25. Iyer RP, Coughlin, JE, Padmanabhan S, Korba, BE, and Myong S (2010) Activation of retinoic acid inducible gene (RIG-I) by nucleotide analogs-a potential novel mechanism for antiviral discovery. Abstracts of the 23rd International Conference on Antiviral Research; 2010 Apr 25-27; San Francisco, CA. International Society for Antiviral Research, Washington, DC.
26. Katze MG, He Y, and Gale M Jr (2002) Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675-687. (Pubitemid 37328725)
27. Li J and Liang Z (2010) The consideration of synthetic short interfering RNA for therapeutic use. Basic Clin Pharmacol Toxicol 106:22-29.
28. Marques JT and Williams BR (2005) Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23:1399-1405. (Pubitemid 41679392)
29. Myong S, Cui S, Cornish PV, Kirchhofer A, Gack MU, Jung JU, Hopfner KP, and Ha T (2009) Cytosolic viral sensor RIG-I is a 5′-triphosphate- dependent translocase on double-stranded RNA. Science 323:1070-1074.
30. Ollis DL and White SW (1987) Structural basis of protein-nucleic acid interactions. Chem Rev 87:981-995.
31. Padmanabhan S, Coughlin JE, Zhang G, Kirk CJ, and Iyer RP (2006) Anti-HBV nucleotide prodrug analogs: synthesis, bioreversibility, and cytotoxicity studies. Bioorg Med Chem Lett 16:1491-1494. (Pubitemid 43197507)
32. Padmanabhan S, Coughlin JE, and Iyer RP (2005) Microwave-assisted functionalization of solid supports. Application in the rapid loading of nucleosides on controlled-pore-glass (CPG). Tetrahedron Lett 46:343-347. (Pubitemid 39602631)
33. Peng B, Andrews J, Nestorov I, Brennan B, Nicklin P, and Rowland M (2001) Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotides ISIS 1082 in rat. Antisense Nucleic Acid drug Dev 11:15-27. (Pubitemid 32199392)
34. Perrillo RP (2004) Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis 24 (Suppl 1):23-29.
35. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Ritzel RG, Mowles DA, Carpenter P, Chen XZ, et al. (2001) Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927.
36. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, and Bose S (2009) Activation of innate immune antiviral responses by Nod2. Nat Immunol 10:1073-1080.
37. Saito M, Go M, and Shirai T (2006) An empirical approach for detecting nucleotide-binding sites on proteins. Protein Eng Des Sel 19:67-75. (Pubitemid 43162258)
38. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, and Gale M Jr (2007) Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci USA 104:582-587. (Pubitemid 46123068)
39. Sanger W (1983) Principles of Nucleic Acid Structure, Springer-Verlag, New York.
40. Shafiee M, Deferme S, Villard AL, Egron D, Gosselin G, Imbach JL, Lioux T, Pompon A, Varray S, Aubertin AM, et al. (2001) New bis(SATE) prodrug of AZT 5′-monophosphate: in vitro anti-HIV activity, stability, and potential oral absorption. J Pharm Sci 90:448-463.
41. Szymkowski DE (1996) Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Disc Today 1:415-428. (Pubitemid 126658983)
42. Tillman LG, Geary RS, and Hardee GE (2008) Oral delivery of antisense oligonucleotides in man. J Pharm Sci 97:225-236.
43. Ting JP, Duncan JA, and Lei Y (2010) How the noninflammasome NLRs function in the innate immune system. Science 327:286-290.
44. Tuschl T (2001) RNA interference and small interfering RNAs. Chembiochem 2:239-245.
45. The United States Pharmacopeia (1993). The National Formulary 18, 23rd ed, pp 1788-1789, United States Pharmacopeial Convention, Inc., Rockville. United States Pharmacopeia, Washington, DC.
46. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, and Masereeuw R (2006) Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34:1393-1397. (Pubitemid 44079881)
47. Wagner RW, Matteucci MD, Grant D, Huang T, and Froehler BC (1996) Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol 14:840-844. (Pubitemid 26239181)
48. Westheimer FH (1968) Pseudo-rotation in the hydrolysis of phosphate esters. Acc Chem Res 1:70-78.
49. Zheng CJ, Sun LZ, Han LY, Ji ZL, Chen X, and Chen YZ (2004) Drug ADME-associated protein database as a resource for facilitating pharmacogenomics research. Drug Dev Res 62:134-142. (Pubitemid 39578607)